

Supplementary Table 3. Sensitivity Analysis: 6-, 12-, 18-, and 24-Month Persistence of the Index Biologic in Patients with Crohn's Disease or Ulcerative Colitis Who Initiated Biologic Treatment during or after Year 2020

| Index treatment | 6 mo persistence with ≥ 6 mo continuous observation | | 12 mo persistence with ≥ 12 mo continuous observation | | 18 mo persistence with ≥ 18 mo continuous observation | | 24 mo persistence with ≥ 24 mo continuous observation | |
|--------------------|---|-------|---|-------|---|-------|---|-------|
| | No. (%) | Total | No. (%) | Total | No. (%) | Total | No. (%) | Total |
| Crohn's disease | | | | | | | | |
| Adalimumab | 100 (90.1) | 111 | 87 (84.5) | 103 | 55 (80.9) | 68 | 29 (70.7) | 41 |
| Infliximab | 105 (98.1) | 107 | 84 (88.4) | 95 | 50 (84.7) | 59 | 25 (75.8) | 33 |
| Vedolizumab | 21 (77.8) | 27 | 16 (59.3) | 27 | 8 (50.0) | 16 | 3 (30.0) | 10 |
| Ustekinumab | 95 (93.1) | 102 | 81 (89.0) | 91 | 53 (88.3) | 60 | 28 (75.7) | 37 |
| Total | 321 (92.5) | 347 | 268 (84.8) | 316 | 166 (81.8) | 203 | 85 (70.2) | 121 |
| Ulcerative colitis | | | | | | | | |
| Adalimumab | 82 (67.8) | 121 | 62 (54.4) | 114 | 38 (47.5) | 80 | 15 (45.5) | 33 |
| Infliximab | 129 (70.9) | 182 | 101 (59.4) | 170 | 57 (52.8) | 108 | 23 (40.4) | 57 |
| Golimumab | 54 (73.0) | 74 | 37 (56.1) | 66 | 25 (54.3) | 46 | 15 (48.4) | 31 |
| Vedolizumab | 164 (81.6) | 201 | 118 (67.4) | 175 | 65 (60.7) | 107 | 27 (56.3) | 48 |
| Ustekinumab | 97 (95.1) | 102 | 78 (83.9) | 93 | 39 (81.3) | 48 | 18 (78.3) | 23 |
| Tofacitinib | 59 (68.6) | 86 | 47 (61.8) | 76 | 22 (45.8) | 48 | 10 (34.5) | 29 |
| Total | 585 (76.4) | 766 | 443 (63.8) | 694 | 246 (56.3) | 437 | 108 (48.9) | 221 |